Novartis is a global Swiss pharmaceutical company headquartered in Basel, Switzerland, with significant research programs in neurodegenerative disease therapeutics. The company has invested in tau-targeted approaches for Alzheimer's disease and progressive supranuclear palsy, particularly through antisense oligonucleotide (ASO) technology.
NIO752 is an antisense oligonucleotide (ASO) developed by Novartis targeting the microtubule-associated protein tau (MAPT) mRNA. Unlike antibody-based approaches that target extracellular tau, ASOs work by reducing the production of tau protein at the transcriptional level.
NIO752 is a gapmer antisense oligonucleotide designed to bind to MAPT mRNA and induce RNase H-mediated degradation. By reducing tau mRNA translation, NIO752 decreases the production of all tau isoforms, including the 3-repeat (3R) and 4-repeat (4R) tau species relevant to different tauopathies.
This mechanism differs from:
NIO752 entered early clinical development for progressive supranuclear palsy and Alzheimer's disease. The program represents Novartis' entry into the tau ASO space, competing with Biogen/Ionis' BIIB080 (IONIS-MAPTRx), which is more advanced in clinical development.
| Compound | Indication | Mechanism | Phase | Status |
|---|---|---|---|---|
| NIO752 | PSP/AD | Anti-MAPT ASO | Early clinical | Active |
NIO752 is being developed as an alternative to the Biogen/Ionis BIIB080 program. Novartis has utilized alternative chemical modifications in NIO752 to potentially enhance potency and durability compared to first-generation ASOs. Early-phase clinical data have demonstrated target engagement as measured by reductions in CSF total tau.
While NIO752 is Novartis' most visible tau-targeted program, the company has broader interests in neurodegeneration:
Novartis has explored brain-specific angiogenesis inhibitor (BAI1/BAI2) as therapeutic targets for various central nervous system disorders.
| Attribute | Detail |
|---|---|
| Headquarters | Basel, Switzerland |
| Founded | 1996 (from Ciba-Geigy/Sandoz merger) |
| CEO | Vas Narasimhan |
| Market Cap | ~$200 billion |
| Employees | ~140,000 |